GSTM1 and anemia (phenotype): Gannon et al. demonstrated that a combination of HBOC-201 and high-dose recombinant human erythropoietin (rHuEpo) for life-threatening anemia (Hb, 3.5 g/dl) improved survival of the patient and a significant increase in Hb to 7.6 g/dl (31).